This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

An Open-Label Study of the Treatment Efficacy of Olanzapine for Tourette’s Disorder

Cathy L. Budman, Alex Gayer, Martin Lesser, Qiuhu Shi, and Ruth D. Bruun

Published: April 1, 2001

Article Abstract

Background: An open-label trial was performed toexplore efficacy and safety of olanzapine, an atypicalneuroleptic with diverse receptor activity including bothdopamine-2 and serotonin-2A and -2C antagonism, for treatment ofTourette’s disorder.

Method: Ten adult patients aged 20 to 44 yearswith Tourette’s disorder were treated using an open-label,flexible dosing schedule for 8 weeks. Three patients whocontinued olanzapine were reevaluated after 6 months. Threesubjects were psychotropic medication naive, 5 patientsexperienced intolerable side effects with conventionalneuroleptics, and 2 patients had remote (>= 10 years)successful response to conventional neuroleptics. Tic severitywas rated by the Yale Global Tic Severity Scale; weight, vitalsigns, and adverse effects were assessed weekly.Electrocardiogram, laboratory studies, and comorbid symptoms,assessed by the Yale-Brown Obsessive Compulsive Scale and ADHDBehavior Checklist for Adults, were measured at baseline and atweek 8.

Results: Two of 10 patients prematurelydiscontinued olanzapine owing to excessive sedation. Of 8patients who completed the 8-week trial, 4 (50%) demonstratedreduction of global tic severity scores by >= 20 points, and 6(75%) demonstrated reductions by >= 10 points. No significantchanges in comorbid symptoms were demonstrated. Sedation, weightgain, increased appetite, dry mouth, and transient asymptomatichypoglycemia were the most common side effects. Tic improvementswere maintained in 3 patients reassessed 6 months later. Finalolanzapine dosages ranged from 2.5 mg to 20 mg daily (mean = 10.9mg/day).

Conclusion: This open-label study suggests thatolanzapine should be explored as a potential alternative toconventional neuroleptic medications for treatment of motor ticsand Tourette’s disorder.

Volume: 62

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF